Literature DB >> 8862966

Antibacterial-induced hepatotoxicity. Incidence, prevention and management.

D K George1, D H Crawford.   

Abstract

Hepatotoxic reactions to antibacterials are rare, occurring with an estimated frequency of between 1 and 10 per 100,000 drug prescriptions for most antibacterials. Although many antibacterial-induced hepatotoxic reactions have a characteristic clinical and biochemical pattern e.g. cholestatic hepatitis (flucloxacillin) or fatty liver (tetracycline), many can also present with a variety of clinicopathological patterns e.g. nitrofurantoin is associated with the development of acute hepatitis, granulomatous hepatitis and chronic active hepatitis. Almost all reactions are idiosyncratic, with no diagnostic laboratory tests to aid the diagnosis. Early diagnosis is essential and requires a vigilant physician to elicit a detailed drug history. Although the outcome is usually good when the offending antibacterial is withdrawn, morbidity may persist for years and fatalities have occurred, particularly when there is a delay in recognising the hepatotoxic antibacterial. There is no specific treatment for antibacterial-induced hepatotoxicity other than withdrawing the implicated drug. For severe disease, however, liver transplantation should be considered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862966     DOI: 10.2165/00002018-199615010-00007

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  50 in total

1.  FATAL LIVER DISEASE AFTER INTRAVENOUS ADMINISTRATION OF TETRACYCLINE IN HIGH DOSAGE.

Authors:  J C SCHULTZ; J S ADAMSON; W W WORKMAN; T D NORMAN
Journal:  N Engl J Med       Date:  1963-11-07       Impact factor: 91.245

2.  Drug related admissions to medical wards: a population based survey.

Authors:  J Hallas; L F Gram; E Grodum; N Damsbo; K Brøsen; T Haghfelt; B Harvald; J Beck-Nielsen; J Worm; K B Jensen
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 3.  Fulminant and subfulminant liver failure: definitions and causes.

Authors:  J Bernuau; B Rueff; J P Benhamou
Journal:  Semin Liver Dis       Date:  1986-05       Impact factor: 6.115

4.  Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases.

Authors:  S Iwarson; J Lindberg; P Lundin
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

5.  Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations.

Authors:  M L Hautekeete; R Brenard; Y Horsmans; J Henrion; L Verbist; G Derue; P Druez; M Omar; M Kockx; H Hubens
Journal:  J Hepatol       Date:  1995-01       Impact factor: 25.083

6.  Fulminant hepatic failure associated with intravenous erythromycin lactobionate.

Authors:  C F Gholson; G H Warren
Journal:  Arch Intern Med       Date:  1990-01

7.  Sex-related variations in the frequency and characteristics of adverse drug reactions.

Authors:  C Domecq; C A Naranjo; I Ruiz; U Busto
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980

8.  Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines.

Authors:  J L Carson; B L Strom; A Duff; A Gupta; M Shaw; F E Lundin; K Das
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

9.  Acute hepatic injury associated with minocycline.

Authors:  A Burette; C Finet; T Prigogine; G De Roy; M Deltenre
Journal:  Arch Intern Med       Date:  1984-07

10.  Erythromycin-associated cholestatic hepatitis.

Authors:  L E Derby; H Jick; D A Henry; A D Dean
Journal:  Med J Aust       Date:  1993-05-03       Impact factor: 7.738

View more
  9 in total

1.  Drug use for non-hepatic associated conditions in patients with liver cirrhosis.

Authors:  M Isabel Lucena; Raúl J Andrade; Gianni Tognoni; Ramón Hidalgo; Felipe Sanchez de la Cuesta
Journal:  Eur J Clin Pharmacol       Date:  2003-04-09       Impact factor: 2.953

2.  Clinical and histologic features of azithromycin-induced liver injury.

Authors:  Melissa A Martinez; Raj Vuppalanchi; Robert J Fontana; Andrew Stolz; David E Kleiner; Paul H Hayashi; Jiezhun Gu; Jay H Hoofnagle; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-09       Impact factor: 11.382

3.  Azithromycin-induced intrahepatic cholestasis.

Authors:  Sreekanth Chandrupatla; Anthony J Demetris; Mordechai Rabinovitz
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 4.  Fluoroquinolone-induced liver injury: three new cases and a review of the literature.

Authors:  Anna Licata; Claudia Randazzo; Ilaria Morreale; Giuseppe Butera; Natale D'Alessandro; Antonio Craxì
Journal:  Eur J Clin Pharmacol       Date:  2012-01-14       Impact factor: 3.064

Review 5.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

6.  Autoimmune hepatitis induced by nitrofurantoin. The importance of the autoantibodies for an early diagnosis of immune disease.

Authors:  Jagannath M Sherigar; Richard Fazio; Minsheng Zuang; Edward Arsura
Journal:  Clin Pract       Date:  2012-10-17

7.  Penicillinase-resistant antibiotics induce non-immune-mediated cholestasis through HSP27 activation associated with PKC/P38 and PI3K/AKT signaling pathways.

Authors:  Audrey Burban; Ahmad Sharanek; Romain Hüe; Marion Gay; Sylvain Routier; André Guillouzo; Christiane Guguen-Guillouzo
Journal:  Sci Rep       Date:  2017-05-12       Impact factor: 4.379

8.  Azithromycin-induced cholestatic hepatitis.

Authors:  Apostolos Koffas; Iain M Murray-Lyon; Roger Williams
Journal:  Oxf Med Case Reports       Date:  2017-06-01

9.  A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman.

Authors:  Caterina Maggioli; Luca Santi; Giacomo Zaccherini; Vittoria Bevilacqua; Francesca Giunchi; Paolo Caraceni
Journal:  Case Reports Hepatol       Date:  2012-01-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.